Oncomed Pharmaceuticals (OMED) Reaches $5.08 After 8.00% Up Move; 14 Analysts Covering Alcoa (AA)

November 14, 2017 - By Henry Gaston

The stock of Oncomed Pharmaceuticals Inc (NASDAQ:OMED) is a huge mover today! About 160,297 shares traded or 4.56% up from the average. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) has declined 70.06% since November 14, 2016 and is downtrending. It has underperformed by 86.76% the S&P500.The move comes after 7 months positive chart setup for the $192.31 million company. It was reported on Nov, 14 by Barchart.com. We have $5.49 PT which if reached, will make NASDAQ:OMED worth $15.38 million more.

Among 24 analysts covering Alcoa Inc. (NYSE:AA), 14 have Buy rating, 0 Sell and 10 Hold. Therefore 58% are positive. Alcoa Inc. had 70 analyst reports since August 4, 2015 according to SRatingsIntel. Deutsche Bank upgraded the shares of AA in report on Wednesday, January 25 to “Hold” rating. The stock of Alcoa Corp (NYSE:AA) has “Overweight” rating given on Thursday, February 2 by JP Morgan. The stock of Alcoa Corp (NYSE:AA) has “Hold” rating given on Wednesday, October 4 by Gabelli. The stock of Alcoa Corp (NYSE:AA) has “Buy” rating given on Friday, February 3 by Bank of America. Citigroup maintained Alcoa Corp (NYSE:AA) rating on Friday, October 20. Citigroup has “Buy” rating and $55 target. The firm has “Buy” rating given on Tuesday, September 8 by Bank of America. The company was maintained on Tuesday, December 22 by Stifel Nicolaus. The rating was maintained by BMO Capital Markets with “Outperform” on Wednesday, September 13. Morgan Stanley maintained the stock with “Overweight” rating in Thursday, June 30 report. The stock of Alcoa Corp (NYSE:AA) has “Market Perform” rating given on Tuesday, January 12 by BMO Capital Markets. See Alcoa Corp (NYSE:AA) latest ratings:

20/10/2017 Broker: Citigroup Rating: Buy Old Target: $53 New Target: $55 Maintain
19/10/2017 Broker: J.P. Morgan Rating: Buy New Target: $60.0
11/10/2017 Broker: Cowen & Co Rating: Hold New Target: $51.0
10/10/2017 Broker: Macquarie Research Rating: Buy New Target: $62.0 Maintain
04/10/2017 Broker: Gabelli Old Rating: Buy New Rating: Hold Old Target: $57.00 New Target: $60.00 Downgrade
04/10/2017 Broker: Bank of America Rating: Buy New Target: $56.0 Upgrade
29/09/2017 Broker: Citigroup Rating: Buy New Target: $53.00 Maintain
22/09/2017 Broker: Berenberg Rating: Hold New Target: $44.0 Downgrade
13/09/2017 Broker: BMO Capital Markets Rating: Outperform Old Target: $4.00 New Target: $6.00 Maintain
12/09/2017 Broker: Deutsche Bank Old Rating: Hold New Rating: Buy Old Target: $44 New Target: $60 Upgrade

About 5.55 million shares traded or 52.47% up from the average. Alcoa Corp (NYSE:AA) has 0.00% since November 14, 2016 and is . It has underperformed by 16.70% the S&P500.

Since May 26, 2017, it had 2 buys, and 0 selling transactions for $471,689 activity. $200,039 worth of stock was bought by AYERS CHRISTOPHER L on Friday, May 26. $271,650 worth of Alcoa Corp (NYSE:AA) shares were bought by Merrin Patrice E.

Alcoa Corporation, formerly Alcoa Upstream Corporation, is engaged in the production of bauxite, alumina and aluminum of various cast and rolled products. The company has market cap of $7.73 billion. The Firm is engaged in the production and management of aluminum and alumina combined through its participation in various aspects of the industry, such as technology, mining, refining, smelting, and recycling. It has a 28.51 P/E ratio. The Company’s divisions include Bauxite, Alumina, Aluminum, Cast Products, Energy and Rolled Products.

Investors sentiment decreased to 0 in 2017 Q2. Its down 0.50, from 0.5 in 2017Q1. It is negative, as 4 investors sold Alcoa Corp shares while 3 reduced holdings. 0 funds opened positions while 0 raised stakes. 484,644 shares or 32.99% less from 723,264 shares in 2017Q1 were reported. Cibc holds 0.05% or 135,600 shares in its portfolio. Carmignac Gestion, a France-based fund reported 340,000 shares. Covington Cap Management accumulated 8,626 shares or 0.02% of the stock. Gemmer Asset Ltd Llc stated it has 0% in Alcoa Corp (NYSE:AA). Focused Wealth Management holds 0% or 29 shares in its portfolio. Vantage Inv Advsr Ltd Co has invested 0% in Alcoa Corp (NYSE:AA).

OncoMed Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $192.31 million. The Firm focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. It currently has negative earnings. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).

Investors sentiment decreased to 0.59 in 2017 Q2. Its down 0.65, from 1.24 in 2017Q1. It dropped, as 26 investors sold Oncomed Pharmaceuticals Inc shares while 23 reduced holdings. 12 funds opened positions while 17 raised stakes. 17.17 million shares or 17.60% more from 14.60 million shares in 2017Q1 were reported. Paloma Prtn Mngmt holds 0% or 78,350 shares in its portfolio. Tower Capital Ltd Company (Trc) holds 0% or 11,490 shares in its portfolio. Barclays Public Limited Liability Corporation owns 66,661 shares. Hodges Cap Mgmt holds 0% or 10,000 shares. Bvf Inc Il has invested 2.28% in Oncomed Pharmaceuticals Inc (NASDAQ:OMED). Birchview L P owns 28,689 shares or 0.05% of their US portfolio. First Eagle Investment Mgmt Llc stated it has 0% of its portfolio in Oncomed Pharmaceuticals Inc (NASDAQ:OMED). Credit Suisse Ag accumulated 44,484 shares or 0% of the stock. Disciplined Growth Mn holds 329,100 shares or 0.02% of its portfolio. Vanguard Grp Inc holds 0% or 995,646 shares in its portfolio. Goldman Sachs stated it has 170,439 shares or 0% of all its holdings. Millennium Management stated it has 0% of its portfolio in Oncomed Pharmaceuticals Inc (NASDAQ:OMED). Zacks Invest Management invested 0% in Oncomed Pharmaceuticals Inc (NASDAQ:OMED). Creative Planning accumulated 0% or 350 shares. Schwab Charles Inv Mngmt accumulated 0% or 46,012 shares.

Among 10 analysts covering OncoMed Pharmaceuticals (NASDAQ:OMED), 5 have Buy rating, 0 Sell and 5 Hold. Therefore 50% are positive. OncoMed Pharmaceuticals has $40 highest and $4.0 lowest target. $9.88’s average target is 94.49% above currents $5.08 stock price. OncoMed Pharmaceuticals had 18 analyst reports since September 9, 2015 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Tuesday, September 26. Jefferies maintained Oncomed Pharmaceuticals Inc (NASDAQ:OMED) on Thursday, August 24 with “Buy” rating. The firm has “Market Perform” rating by BMO Capital Markets given on Tuesday, April 11. The firm earned “Buy” rating on Monday, April 18 by Cantor Fitzgerald. The stock of Oncomed Pharmaceuticals Inc (NASDAQ:OMED) has “Outperform” rating given on Friday, December 4 by Wells Fargo. Jefferies maintained Oncomed Pharmaceuticals Inc (NASDAQ:OMED) on Wednesday, August 10 with “Buy” rating. The firm has “Market Outperform” rating by JMP Securities given on Wednesday, March 9. SunTrust initiated Oncomed Pharmaceuticals Inc (NASDAQ:OMED) rating on Tuesday, December 20. SunTrust has “Buy” rating and $16 target. The company was downgraded on Monday, January 25 by Leerink Swann. The company was initiated on Wednesday, September 9 by Jefferies.

Analysts await Oncomed Pharmaceuticals Inc (NASDAQ:OMED) to report earnings on March, 14. They expect $-0.32 EPS, up 54.29% or $0.38 from last year’s $-0.7 per share. After $-0.28 actual EPS reported by Oncomed Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 14.29% negative EPS growth.

Since May 16, 2017, it had 3 insider buys, and 2 sales for $143,074 activity. LASERSOHN JACK W bought 34,614 shares worth $116,639. $24,714 worth of stock was sold by ROOT JONATHAN D on Tuesday, May 16. The insider KARSEN PERRY A bought $34,588.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com